Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia

European Respiratory Journal

Volumn 45, Issue 6, 2015, Pages 1632-1641

  Rodrigo, Chamira ^a   Bewick, Thomas ^a   Sheppard, Carmen ^b   Greenwood, Sonia ^a   Mckeever, Tricia M ^c   Trotter, Caroline L ^d   Slack, Mary ^b   George, Robert ^b   Lim, Wei Shen ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; PREVENAR13;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; FEMALE; HUMAN; IMMUNOASSAY; INCIDENCE; INCIDENCE RATE RATIO; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; COMMUNITY-ACQUIRED INFECTIONS; HOSPITALIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; SEROGROUP; STREPTOCOCCUS PNEUMONIAE;

EID: 84930397333     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00183614     Document Type: Article

References (33)

1. Strehlow MC, Emond SD, Shapiro NI, et al. National study of emergency department visits for sepsis, 1992 to 2001. Ann Emerg Med 2006; 48: 326-331.e3.
2. Trotter CL, Stuart JM, George R, et al. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis 2008; 14: 727-733.
3. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56: 296-301.
4. van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005; 24: 241-249.
5. Public Health England. Pneumococcal disease: guidance, data and analysis. www.gov.uk/government/collections/pneumococcal-disease-guidance-data-and-analysis Date last accessed: September 2013.
6. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11: 760-768.
7. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41.
8. Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia. J Infect Dis 2013; 208: 1813-1820.
9. Rozenbaum MH, van Hoek AJ, Fleming D, et al. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ 2012; 345: e6879.
10. Sinclair A, Xie X, Teltscher M, et al. Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae. J Clin Microbiol 2013; 51: 2303-2310.
11. Sheppard CL, Harrison TG, Smith MD, et al. Development of a sensitive, multiplexed immunoassay using xMAP beads for detection of serotype-specific Streptococcus pneumoniae antigen in urine samples. J Med Microbiol 2011; 60: 49-55.
12. Ewig S, Schlochtermeier M, Goke N, et al. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest 2002; 121: 1486-1492.
13. Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004; 39: 165-169.
14. Nottingham City Council. Nottingham Insight: Census 2011. 2011. www.nottinghaminsight.org.uk/insight/key-datasets/census-2011.aspx. Date last accessed: May 2014.
15. Public Health England. Vaccine uptake guidance and the latest coverage data. 2014. www.gov.uk/government/collections/vaccine-uptake Date last accessed: June 2014.
16. Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369: 155-163.
17. Simonsen L, Taylor RJ, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio 2011; 2: e00309-e00310.
18. El Turki A, Hsia Y, Saxena S, et al. Impact of 7-valent pneumococcal conjugate vaccine (PVC-7) on the incidence and treatment of pneumonia diagnosed in primary care in children and adolescents in UK. Arch Dis Child 2011; 96: Suppl. 1, A5.
19. Kaye P, Malkani R, Slack M, et al. Real-time surveillance to evaluate the impact of the pneumococcal conjugate vaccine (PCV) in England and Wales. Pneumonia 2014; 3: 174.
20. Public Health England. Laboratory reports to HPA Colindale of infections due to Mycoplasma pneumoniae England and Wales by date of report 1991-2013 (4 weekly). Available from: www.gov.uk/mycoplasma Date last accessed: June 2014. Date last updated.
21. Chalker V, Stocki T, Litt D, et al. Increased detection of Mycoplasma pneumoniae infection in children in England and Wales, October 2011 to January 2012. Euro Surveill 2012; 17: pii 20081.
22. Public Health England. Health Protection-Collection. Seasonal influenza: guidance, data and analysis. www.gov.uk/government/collections/seasonal-influenza-guidance-data-and-analysis#epidemiology Date last accessed: November. Date last updated July 14, 2014.
23. Ewig S, Birkner N, Strauss R, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-1069.
24. Wroe PC, Finkelstein JA, Ray GT, et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis 2012; 205: 1589-1592.
25. Melin M, Jarva H, Siira L, et al. Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun 2009; 77: 676-684.
26. Angoulvant F, Levy C, Grimprel E, et al. Early impact of 13-Valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis 2014; 58: 918-924.
27. Okade H, Funatsu T, Eto M, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and susceptibility trends of pediatric non-invasive Streptococcus pneumoniae isolates in Tokai, Japan over a 5-year period. J Infect Chemother 2014; 20: 423-428.
28. Bewick T, Sheppard C, Greenwood S, et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax 2012; 67: 540-545.
29. Public Health England. Longer lives. http://healthierlives.phe.org.uk/topic/mortality Date last accessed: July 2014.
30. Office for National Statistics. 2011 Census-Ethnicity. www.ons.gov.uk/ons/interactive/census-map-2-1-ethnicity/index.html Date last accessed: July 2014.
31. Price L, Anwar M, Srikanthan K, et al. P244 accuracy of admission diagnosis of pneumonia. Thorax 2013; 68: Suppl. 3, A187.
32. Pink KL, Mitchell I, Davies HE. Clinical observation in acute and chronic lung infection: P17 the accuracy of a diagnosis of pneumonia in a UK teaching hospital. Thorax 2012; 67: Suppl. 2, A71.
33. Simonsen L, Taylor RJ, Schuck-Paim C, et al. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med 2014; 2: 387-394.